RU2020107732A - Схема дозирования модулятора s1p с немедленным высвобождением - Google Patents

Схема дозирования модулятора s1p с немедленным высвобождением Download PDF

Info

Publication number
RU2020107732A
RU2020107732A RU2020107732A RU2020107732A RU2020107732A RU 2020107732 A RU2020107732 A RU 2020107732A RU 2020107732 A RU2020107732 A RU 2020107732A RU 2020107732 A RU2020107732 A RU 2020107732A RU 2020107732 A RU2020107732 A RU 2020107732A
Authority
RU
Russia
Prior art keywords
per day
siponimod
patient
treatment
dosage form
Prior art date
Application number
RU2020107732A
Other languages
English (en)
Russian (ru)
Inventor
Эрик ЛЕГАНЬНЕ
Эрик Валлстрём
Филипп Мишель Рене БУЙО
Эмерик Рейно
Франк ДАЛЬКЕ
Original Assignee
Новартис Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52988364&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2020107732(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Новартис Аг filed Critical Новартис Аг
Publication of RU2020107732A publication Critical patent/RU2020107732A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
RU2020107732A 2014-04-10 2015-04-08 Схема дозирования модулятора s1p с немедленным высвобождением RU2020107732A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461977816P 2014-04-10 2014-04-10
US61/977,816 2014-04-10

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2016143979A Division RU2715734C2 (ru) 2014-04-10 2015-04-08 Схема дозирования модулятора s1p с немедленным высвобождением

Publications (1)

Publication Number Publication Date
RU2020107732A true RU2020107732A (ru) 2020-03-30

Family

ID=52988364

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2020107732A RU2020107732A (ru) 2014-04-10 2015-04-08 Схема дозирования модулятора s1p с немедленным высвобождением
RU2016143979A RU2715734C2 (ru) 2014-04-10 2015-04-08 Схема дозирования модулятора s1p с немедленным высвобождением

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2016143979A RU2715734C2 (ru) 2014-04-10 2015-04-08 Схема дозирования модулятора s1p с немедленным высвобождением

Country Status (16)

Country Link
US (4) US20170027907A1 (enExample)
EP (3) EP4074312B1 (enExample)
JP (1) JP6674903B2 (enExample)
KR (2) KR20160141841A (enExample)
CN (2) CN106456552A (enExample)
AU (2) AU2015246036A1 (enExample)
CA (1) CA2943598C (enExample)
CL (1) CL2016002562A1 (enExample)
IL (2) IL305337A (enExample)
MX (1) MX2016013245A (enExample)
PH (1) PH12016501965A1 (enExample)
RU (2) RU2020107732A (enExample)
SG (1) SG11201607894RA (enExample)
TW (1) TW201622721A (enExample)
WO (1) WO2015155709A1 (enExample)
ZA (1) ZA201606519B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2699580T3 (enExample) 2014-01-24 2018-02-24
EP4074312B1 (en) * 2014-04-10 2026-02-25 Novartis AG Siponimod immediate release dosage regimen for treating autoimmune diseases
US11629124B2 (en) 2017-03-09 2023-04-18 Novartis Ag Solid forms comprising an oxime ether compound, compositions and methods of use thereof
US11434200B2 (en) 2017-03-09 2022-09-06 Novartis Ag Solid forms comprising an oxime ether compound and a coformer, compositions and methods of use thereof
EP3687530A1 (en) * 2017-09-29 2020-08-05 Novartis AG Dosing regimen of siponimod
RU2020114751A (ru) * 2017-09-29 2021-10-29 Новартис Аг Схема введения доз сипонимода
SI3758708T1 (sl) 2018-03-01 2025-04-30 Astrazeneca Ab Farmacevtski sestavki, ki vsebujejo (2S)-{(1S)-1-ciano-2-[4-(3-metil-2-okso-2,3-dihidro-1,3-benzoksazol-5-il)fenil]etil}-1,4-oksazepan-2-karboksamid
CA3106269A1 (en) 2018-07-17 2020-01-23 Insmed Incorporated Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating lupus nephritis
CN109908095A (zh) * 2019-04-08 2019-06-21 肇庆学院 一种西尼莫德片剂及制备方法
WO2021084068A1 (en) 2019-10-31 2021-05-06 Idorsia Pharmaceuticals Ltd Combination of a cxcr7 antagonist with an s1p1 receptor modulator
US11135197B2 (en) 2020-02-07 2021-10-05 Argentum Pharmaceuticals Llc Dosage regimen of an S1P receptor modulator
EP4646265A1 (en) 2023-01-06 2025-11-12 Insmed Incorporated Novel, reversible dpp1 inhibitors and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160064245A (ko) * 2008-12-18 2016-06-07 노파르티스 아게 1-［4-［1-(4-시클로헥실-3-트리플루오로메틸-벤질옥시이미노)-에틸］-2-에틸-벤질］-아제티딘-3-카르복실산의 헤미푸마레이트 염
AR074826A1 (es) * 2008-12-22 2011-02-16 Novartis Ag Regimen de dosificacion para un agonista de los receptores de s1p
CA2747992C (en) 2008-12-22 2017-11-07 Novartis Ag Dosage regimen of an s1p receptor agonist
AU2010300919A1 (en) * 2009-09-29 2012-03-22 Novartis Ag Dosage regimen of an S1P receptor modulator
PH12013501442B1 (en) * 2011-01-07 2018-04-20 Novartis Ag Immunosuppressant formulations
WO2012095853A1 (en) * 2011-01-10 2012-07-19 Novartis Pharma Ag Modified release formulations comprising sip receptor modulators
BR112014009141A8 (pt) * 2011-10-21 2017-06-20 Novartis Ag regime de dosagem para um modulador ou agonista do receptor s1p
EP4074312B1 (en) * 2014-04-10 2026-02-25 Novartis AG Siponimod immediate release dosage regimen for treating autoimmune diseases

Also Published As

Publication number Publication date
US20250041266A1 (en) 2025-02-06
AU2015246036A1 (en) 2016-10-13
CN106456552A (zh) 2017-02-22
EP4074312B1 (en) 2026-02-25
MX2016013245A (es) 2017-01-16
JP6674903B2 (ja) 2020-04-01
CA2943598C (en) 2023-03-07
AU2020203107A1 (en) 2020-05-28
RU2715734C2 (ru) 2020-03-03
KR20160141841A (ko) 2016-12-09
EP4074312A1 (en) 2022-10-19
EP3129020A1 (en) 2017-02-15
IL247986A0 (en) 2016-11-30
US20220016076A1 (en) 2022-01-20
CL2016002562A1 (es) 2017-07-28
CN116650467A (zh) 2023-08-29
AU2020203107B2 (en) 2021-10-21
JP2017510607A (ja) 2017-04-13
US20170027907A1 (en) 2017-02-02
EP3831378A1 (en) 2021-06-09
KR20220156981A (ko) 2022-11-28
WO2015155709A1 (en) 2015-10-15
SG11201607894RA (en) 2016-10-28
IL305337A (en) 2023-10-01
US20190054065A1 (en) 2019-02-21
RU2016143979A (ru) 2018-05-14
TW201622721A (zh) 2016-07-01
RU2016143979A3 (enExample) 2018-11-12
ZA201606519B (en) 2017-11-29
CA2943598A1 (en) 2015-10-15
PH12016501965A1 (en) 2017-01-09

Similar Documents

Publication Publication Date Title
RU2020107732A (ru) Схема дозирования модулятора s1p с немедленным высвобождением
Croft et al. Efficacy and safety of vilazodone in major depressive disorder: a randomized, double-blind, placebo-controlled trial
JP2017510607A5 (enExample)
JP6446552B2 (ja) 体重と体脂肪減少に用いられる組成物およびその医薬品と使用
TW201615221A (zh) 炎症用藥臨床新應用
PH12015502691A1 (en) Use of high dose pridopidine for treating huntington's disease
RU2011138490A (ru) Фармацевтические композиции с мгновенным высвобождением, содержащие оксикодон и налоксон
JP2016520653A5 (enExample)
RU2012128109A (ru) Способы проведения терапии потери веса у пациентов с доминирующей депрессией (варианты)
MX2023001014A (es) Composiciones farmaceuticas que comprenden venglustat.
FI3352735T3 (fi) Pitkitetysti vapauttavia olantsapiiniformulaatioita
RS60240B1 (sr) Postupci i kompozicije za lečenje depresije korišćenjem ciklobenzaprina
Hattori et al. Sustained efficacy of apomorphine in Japanese patients with advanced Parkinson's disease
RU2008119454A (ru) Лекарственное средство для защиты моторного нейрона у пациентов с боковым амиотрофическим склерозом
JP2016505050A5 (enExample)
HRP20240812T1 (hr) Oblici doziranja i terapijska primjena l-4-klorokinurenina
CN105209044B (zh) 用于疼痛病症的治疗性米氮平组合物
JP2019535830A5 (enExample)
US20190224208A1 (en) Pharmaceutical composition for treating premature ejaculation and method for treating premature ejaculation
Jangjoo et al. Effect of preoperative rectal indomethacin on postoperative pain reduction after open appendectomy
Senanarong et al. Safety and tolerability of galantamine in possible Alzheimer’s disease with or without cerebrovascular disease and vascular dementia in Thai patients
RU2015128914A (ru) Составы лоразепама с контролируемым высвобождением
Safety Higher-Dose Alzheimer’s Drug Gets FDA Approval
ZA202206042B (en) Treating behavioral and psychological symptoms in dementia patients
FI4065134T3 (fi) Rautasuksinaatin antaminen suun kautta käytettäväksi raudanpuutoksen hoidossa potilailla, joilla on sydämen vajaatoiminta